SCHEMBL8070286

SCHEMBL8070286

N#Cc1cncc(-c2ccccc2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 5/20 0.55
CYP11B1 P15538 4/20 0.55
SMN1; SMN2 Q16637 3/20 0.49
KMT2A Q03164 3/20 0.49
GLA P06280 2/20 0.49
MEN1 O00255 2/20 0.49
POLB P06746 1/20 0.49
HPGD P15428 1/20 0.49
KDM4E B2RXH2 4/20 0.46
MAPT P10636 2/20 0.46
GAA P10253 2/20 0.46
LMNA P02545 2/20 0.45
L3MBTL1 Q9Y468 3/20 0.44
ADRB2 P07550 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
IRAK4 Q9NWZ3 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30338462 0.84 CYP11B2 (0.51) CYP11B2CYP11B1SMN1; SMN2GLAHPGD
SCHEMBL21044154 0.81 CYP11B2 (0.56) CYP11B2CYP11B1SMN1; SMN2KMT2AGLA
SCHEMBL28145764 0.80 CYP11B1 (0.55) CYP11B2CYP11B1SMN1; SMN2KMT2AGLA
SCHEMBL13996075 0.79 MEN1 (0.62) CYP11B2CYP11B1SMN1; SMN2KMT2AMEN1
SCHEMBL31754524 0.77 KDM4E (0.48) CYP11B2CYP11B1SMN1; SMN2KMT2AGLA
SCHEMBL317148 0.76 KMT2A (0.60) SMN1; SMN2KMT2AGLAMEN1POLB
SCHEMBL3761705 0.74 CYP11B1 (0.46) CYP11B2CYP11B1IRAK4
SCHEMBL21044544 0.74 CYP11B2 (0.52) CYP11B2CYP11B1KMT2AMEN1KDM4E
SCHEMBL3293682 0.73 CYP11B1 (0.44) CYP11B2CYP11B1IRAK4
SCHEMBL27901846 0.73 KDM4E (0.58) SMN1; SMN2KMT2AGLAMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1938296-A Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists ASTELLAS PHARMA INC (JP) 2007-03-28 CN disclosed
EP-1023278-A1 PROCESS FOR PREPARING SUBSTITUTED PYRAZINE COMPOUNDS Abbott Laboratories (US) 2000-08-02 EP disclosed
WO-1999019314-A1 PROCESS FOR PREPARING SUBSTITUTED PYRAZINE COMPOUNDS ABBOTT LABORATORIES (US) 1999-04-22 WO disclosed